Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis
Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis
复制标题
DOI：
10.1111/j.1398-9995.2011.02735.x
复制
发表时间：
2012-02-01
期刊：
影响因子：
12.4
通讯作者：
Jang, T. Y.
中科院分区：
文献类型：
--
作者：
Kim, Y. H.;Yang, T. Y.;Jang, T. Y.
背景：白细胞介素（IL）-33参与Th 2免疫应答，在鼻变态反应中起重要作用。因此，我们旨在研究抗IL-33对变应性鼻炎（AR）的治疗潜力。方法：BALB/c小鼠24只。A组（对照组，n = 6）致敏后用生理盐水激发。B组[卵清蛋白（OVA）组，n = 6]小鼠接受腹腔内和鼻腔内OVA激发。C组（对照IgG组，n = 6），在卵蛋白攻击前腹腔注射兔对照IgG。D组（抗IL-33组，n = 6），在激发前注射抗IL-33。我们评估了鼻搔事件的数量和外部形态学;血清总IgE和OVA特异性IgE;支气管肺泡灌洗液（BAL）中嗜酸性粒细胞、中性粒细胞和淋巴细胞的数量;鼻腔组织病理学检查;以及BAL液中的IL-4、IL-5和IL-13。结果：抗IL-33治疗显著减少了鼻搔事件，并改善了皮肤剥脱。D组血清总IgE和OVA特异性IgE显著降低。BAL液中嗜酸性粒细胞数量也显著减少。D组鼻腔嗜酸性粒细胞浸润明显减少。治疗后BALF中IL-4、IL-5、IL-13也明显降低。结论：抗IL-33抗体对实验性AR具有治疗作用。
Background: Interleukin (IL)-33 is involved in the Th2 immune response and could play an essential role in nasal allergy. Therefore, we aimed to investigate the therapeutic potential of anti-IL-33 for allergic rhinitis (AR). Methods: Twenty-four BALB/c mice were used. In group A (control group, n = 6), mice were sensitized and challenged with saline. Group B [ovalbumin (OVA) group, n = 6] mice received intraperitoneal and intranasal OVA challenge. In group C (control IgG group, n = 6), mice were injected intraperitoneally with rabbit control IgG before OVA challenge. In group D (anti-IL-33 group, n = 6), anti-IL-33 was injected before challenge. We evaluated the number of nose-scratching events and external morphology; serum total and OVA-specific IgE; number of eosinophils, neutrophils, and lymphocytes in bronchoalveolar lavage (BAL) fluid; histopathologic examination of nasal cavity; and IL-4, IL-5, and IL-13 in BAL fluid. Results: Anti-IL-33 treatment significantly reduced the nose-scratching events and ameliorated skin denudation. Serum total and OVA-specific IgE was significantly decreased in group D. The number of eosinophils in BAL fluid was also significantly decreased. Eosinophilic infiltration in the nasal cavity was significantly decreased in group D. IL-4, IL-5, and IL-13 in BAL fluid were also significantly decreased after treatment. Conclusions: Anti-IL-33 antibody has a therapeutic potential for experimental AR.